By Jaime Llinares Taboada
Scancell Holdings PLC said Tuesday that it will start a Phase 1 study on its two Covid-19 vaccine candidates.
The developer of novel immunotherapies said candidates SN15 and SN17 could offer improved protection against new SARS-Cov-2 variants of concern, due to the inclusion of highly conserved nucleocapsid N antigen.
The first part of the trial will be conducted at the University of Cape Town Lung Institute in South Africa with unvaccinated healthy volunteers, to assess the safety and immunogenicity of the two candidates. If that is successful, Scancell will seek approval for an extension of the study in the U.K. for healthy volunteers who have already received two doses of an approved vaccine.
Scancell is developing these vaccine candidates as part of the Covidity program with the Centre for Research on Global Virus Infections and the University of Nottingham.
Write to Jaime Llinares Taboada at firstname.lastname@example.org; @JaimeLlinaresT
View more information: https://www.marketwatch.com/story/scancell-to-begin-covidity-vaccine-trials-on-volunteers-271624343510